Research programme: AstraZeneca 4 Programs - AstraZeneca and Pieris Pharmaceuticals

Drug Profile

Research programme: AstraZeneca 4 Programs - AstraZeneca and Pieris Pharmaceuticals

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pieris Pharmaceuticals
  • Developer AstraZeneca; Pieris Pharmaceuticals
  • Class Lipocalins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Respiration disorders

Most Recent Events

  • 12 Jun 2017 Pieris Pharmaceuticals' collaboration with AstraZeneca gets clearance post-expiration of the Hart-Scott-Rodino Act waiting period
  • 03 May 2017 Early research in Respiration disorders in United Kingdom (Inhalation) (Pieris Pharmaceuticals Pipeline, May 2017)
  • 03 May 2017 Early research in Respiration disorders in USA (Inhalation) (Pieris Pharmaceuticals Pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top